These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 25475459)

  • 1. Comparison of outcomes after cardioversion or atrial fibrillation ablation in patients with differing periprocedural anticoagulation regimens.
    Kochhäuser S; Khaykin Y; Beardsall J; Juta R; Hache P; Trought K; Lenton-Brym T; Tsang B; Pantano A; Beardsall M; Wulffhart Z; Verma A
    Can J Cardiol; 2014 Dec; 30(12):1541-6. PubMed ID: 25475459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial.
    Piccini JP; Stevens SR; Lokhnygina Y; Patel MR; Halperin JL; Singer DE; Hankey GJ; Hacke W; Becker RC; Nessel CC; Mahaffey KW; Fox KA; Califf RM; Breithardt G;
    J Am Coll Cardiol; 2013 May; 61(19):1998-2006. PubMed ID: 23500298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial.
    Di Biase L; Burkhardt JD; Santangeli P; Mohanty P; Sanchez JE; Horton R; Gallinghouse GJ; Themistoclakis S; Rossillo A; Lakkireddy D; Reddy M; Hao S; Hongo R; Beheiry S; Zagrodzky J; Rong B; Mohanty S; Elayi CS; Forleo G; Pelargonio G; Narducci ML; Dello Russo A; Casella M; Fassini G; Tondo C; Schweikert RA; Natale A
    Circulation; 2014 Jun; 129(25):2638-44. PubMed ID: 24744272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
    Providência R; Marijon E; Albenque JP; Combes S; Combes N; Jourda F; Hireche H; Morais J; Boveda S
    Europace; 2014 Aug; 16(8):1137-44. PubMed ID: 24550347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis of risk of stroke and thrombo-embolism with rivaroxaban versus vitamin K antagonists in ablation and cardioversion of atrial fibrillation.
    Nairooz R; Sardar P; Pino M; Aronow WS; Sewani A; Mukherjee D; Paydak H; Maskoun W
    Int J Cardiol; 2015; 187():345-53. PubMed ID: 25839640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contemporary Management of Direct Oral Anticoagulants During Cardioversion and Ablation for Nonvalvular Atrial Fibrillation.
    Trujillo TC; Dobesh PP; Crossley GH; Finks SW
    Pharmacotherapy; 2019 Jan; 39(1):94-108. PubMed ID: 30548542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion.
    Ezekowitz MD; Cappato R; Klein AL; Camm AJ; Ma CS; Le Heuzey JY; Talajic M; Scanavacca MI; Vardas PE; Kirchhof P; Hohnloser SH; Hemmrich M; Lanius V; Meng IL; Wildgoose P; van Eickels M
    Am Heart J; 2014 May; 167(5):646-52. PubMed ID: 24766973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.
    Lakkireddy D; Reddy YM; Di Biase L; Vallakati A; Mansour MC; Santangeli P; Gangireddy S; Swarup V; Chalhoub F; Atkins D; Bommana S; Verma A; Sanchez JE; Burkhardt JD; Barrett CD; Baheiry S; Ruskin J; Reddy V; Natale A
    J Am Coll Cardiol; 2014 Mar; 63(10):982-8. PubMed ID: 24412445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation.
    Eitel C; Koch J; Sommer P; John S; Kircher S; Bollmann A; Arya A; Piorkowski C; Hindricks G
    Europace; 2013 Nov; 15(11):1587-93. PubMed ID: 23703362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Oral Anticoagulants in Direct Current Cardioversion for Atrial Fibrillation.
    Femia G; Fetahovic T; Shetty P; Lee A
    Heart Lung Circ; 2018 Jul; 27(7):798-803. PubMed ID: 28802808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial.
    Chi G; Kerneis M; Kalayci A; Liu Y; Mehran R; Bode C; Halperin JL; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Peterson ED; Fox KAA; Gibson CM
    Am Heart J; 2018 Sep; 203():17-24. PubMed ID: 30015064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).
    Flaker G; Lopes RD; Al-Khatib SM; Hermosillo AG; Hohnloser SH; Tinga B; Zhu J; Mohan P; Garcia D; Bartunek J; Vinereanu D; Husted S; Harjola VP; Rosenqvist M; Alexander JH; Granger CB;
    J Am Coll Cardiol; 2014 Mar; 63(11):1082-7. PubMed ID: 24211508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low stroke risk after elective cardioversion of atrial fibrillation: an analysis of the Flec-SL trial.
    Apostolakis S; Haeusler KG; Oeff M; Treszl A; Andresen D; Borggrefe M; Lip GY; Meinertz T; Parade U; Samol A; Steinbeck G; Wegscheider K; Breithardt G; Kirchhof P
    Int J Cardiol; 2013 Oct; 168(4):3977-81. PubMed ID: 23871349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of oral anticoagulation use with cardioversion in clinical practice.
    Geurink K; Holmes D; Ezekowitz MD; Pieper K; Fonarow G; Kowey PR; Reiffel JA; Singer DE; Freeman J; Gersh BJ; Mahaffey KW; Hylek EM; Naccarelli G; Piccini JP; Peterson ED; Pokorney SD
    Heart; 2021 Apr; 107(8):642-649. PubMed ID: 32591363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of stroke after catheter ablation versus cardioversion for atrial fibrillation: A propensity-matched study of 24,244 patients.
    Noseworthy PA; Kapa S; Deshmukh AJ; Madhavan M; Van Houten H; Haas LR; Mulpuru SK; McLeod CJ; Asirvatham SJ; Friedman PA; Shah ND; Packer DL
    Heart Rhythm; 2015 Jun; 12(6):1154-61. PubMed ID: 25708883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral anticoagulant therapy for stroke prevention in patients with atrial fibrillation undergoing ablation: results from the First European Snapshot Survey on Procedural Routines for Atrial Fibrillation Ablation (ESS-PRAFA).
    Potpara TS; Larsen TB; Deharo JC; Rossvoll O; Dagres N; Todd D; Pison L; Proclemer A; Purefellner H; Blomström-Lundqvist C;
    Europace; 2015 Jun; 17(6):986-93. PubMed ID: 26023177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio.
    Di Biase L; Burkhardt JD; Mohanty P; Sanchez J; Horton R; Gallinghouse GJ; Lakkireddy D; Verma A; Khaykin Y; Hongo R; Hao S; Beheiry S; Pelargonio G; Dello Russo A; Casella M; Santarelli P; Santangeli P; Wang P; Al-Ahmad A; Patel D; Themistoclakis S; Bonso A; Rossillo A; Corrado A; Raviele A; Cummings JE; Schweikert RA; Lewis WR; Natale A
    Circulation; 2010 Jun; 121(23):2550-6. PubMed ID: 20516376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter.
    Yadlapati A; Groh C; Passman R
    Am J Cardiol; 2014 Apr; 113(8):1362-3. PubMed ID: 24576547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants.
    Brinkmeier-Theofanopoulou M; Tzamalis P; Wehrkamp-Richter S; Radzewitz A; Merkel M; Schymik G; van Mark G; Bramlage P; Schmitt C; Luik A
    BMC Cardiovasc Disord; 2018 Apr; 18(1):71. PubMed ID: 29703158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry.
    Papp J; Zima E; Bover R; Karaliute R; Rossi A; Szymanski C; Troccoli R; Schneider J; Fagerland MW; Camm AJ; Atar D
    Eur Heart J Cardiovasc Pharmacother; 2017 Jul; 3(3):147-150. PubMed ID: 28329309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.